Meeting
2023 ASCO Breakthrough
Personalized medicine for brain metastases (BrMets) through patient-derived organoid (PDO) drug testing.
Authors
Aki Morikawa
University of Michigan, Ann Arbor, MI
Aki Morikawa , Habib Serhan , Aaron M. Udager , Liwei Bao , Zhaoping Qin , Xu Cheng , Jason Heth , Matthew Soellner , Sofia Merajver , Nathan Merrill
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Breast Cancer,Central Nervous System Tumors,Developmental Therapeutics,Genitourinary Cancer,Hematologic Malignancies,Thoracic Cancers,Other Malignancies or Topics
Sub Track
Omics for precision medicine
Citation
JCO Global Oncology 9, 2023 (suppl 1; abstr 11)
DOI
10.1200/GO.2023.9.Supplement_1.11
Abstract #
11
Poster Bd #
B5
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Impact of cholangiocarcinoma (CC) molecular heterogeneity on outcome during first-line chemotherapy and access to targeted therapies in early clinical trials (CT).
First Author: Helena Verdaguer
Poster
2017 Genitourinary Cancers Symposium
Circulating tumor (ct)-DNA alterations in advanced urothelial carcinoma: Association with outcomes and evolution with therapy.
First Author: Petros Grivas
Poster
2015 ASCO Annual Meeting
Molecular profiling of mucinous epithelial ovarian carcinomas (mEOC): Opportunities for clinical trials.
First Author: Michael Friedlander
Poster
2014 ASCO Annual Meeting
Evidence of PIK3CA and TP53 co-mutation in breast cancer identification on next-generation sequencing (NGS) of ERBB2 (HER2)-amplified residual disease following preoperative anti-HER2 therapy.
First Author: Frankie Ann Holmes